Favrille - Specifid: they make it personal!

Favrille, the San Diego biotechnology company, is laying off 132 of its 144 employees, including six of its eight executive officers. The move comes after the company announced this week that it had discontinued development of its lead drug, Specifid, after it failed to show benefit in a Phase 3 clinical trial in non-Hodgkin lymphoma.